We are live on ! Find out more
IMVT icon

Immunovant
IMVT

Fund managers haven’t disclosed any holdings of IMVT yet.

IMVT Hedge Fund Activity: Q1 2026 in Review

215 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2026, worth a combined $2.75B — down 0.52% from $2.76B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IMVT positions and 24 closed out — a net gain of 22 holders — while 93 added to existing stakes and 40 trimmed.

The largest buyer was TCG Crossover Management, adding an estimated $72.4M. The largest seller was Armistice Capital, cutting an estimated $56.5M.

  • 215 institutional investors held Immunovant (IMVT) as of Q1 2026, up from 196 in Q4 2025.
  • Funds reported $2.75B of Immunovant stock for Q1 2026, down 0.52% quarter-over-quarter.
  • 46 funds opened new Immunovant positions in Q1 2026 and 24 closed out, a net change of +22 holders.
  • The largest Immunovant buyer in Q1 2026 was TCG Crossover Management, an estimated $72.4M added.
  • The largest Immunovant seller in Q1 2026 was Armistice Capital, an estimated $56.5M sold.

Based on aggregated 13F filings for Q1 2026.